The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Significantly improving HRQL and neurocognition in high-risk sickle cell following familial ASCT
Mitchell Cairo, MD, of New York Medical College, Valhalla, NY, discusses the NYMC-571 trial (NCT02675959). This showed significantly improved long-term health-related quality of life and neurocognition in high-risk sickle cell disease patients following familial haploidentical stem cell transplantation that used CD34-enriched and CD3 mononuclear addback. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
